ArticlePharmaceutics2024

A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule.

Iraj Hosseini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.